“`html
Bioxytran (OTCQB: BIXT) is making waves with a significant scientific advancement: the publication of “Body Oxygen Homeostasis and Mitochondrial Function from Animal Models to Clinical Applications” by Prof. Avraham Mayevsky. This pivotal research sheds light on the limitations of current peripheral oxygen measurements and introduces a game-changing paradigm shift towards tissue-specific oxygenation monitoring. In essence, it’s about getting oxygen where it’s needed most.
The company’s MDX Viewer technology, paired with their Universal Oxygen Carrier (UOC) and BXT-25 development programs, aims to revolutionize treatment strategies for debilitating conditions like stroke and Alzheimer’s disease. This technology is poised to serve as a crucial biomarker in upcoming BXT-25 clinical trials, potentially transforming how oxygen delivery is measured and managed in critical situations.
Bioxytran (OTCQB: BIXT) ha annunciato un importante avanzamento scientifico con la pubblicazione di un libro rivoluzionario del Prof. Avraham Mayevsky sulla ossigenazione tissutale e la funzione mitocondriale. La ricerca evidenzia i limiti delle attuali misurazioni periferiche dell’ossigeno e propone un cambio di paradigma verso il monitoraggio dell’ossigenazione specifico per i tessuti.
La tecnologia MDX Viewer della società, unita al loro Universal Oxygen Carrier (UOC) e ai programmi di sviluppo BXT-25, mira a rivoluzionare gli approcci terapeutici per patologie come ictus e morbo di Alzheimer. La tecnologia fungerà da biomarcatore cruciale nei prossimi trial clinici BXT-25, potenzialmente trasformando il modo in cui la somministrazione di ossigeno viene misurata e gestita nelle condizioni critiche.
Bioxytran (OTCQB: BIXT) anunció un importante avance científico con la publicación de un libro innovador del Prof. Avraham Mayevsky sobre la oxigenación tisular y la función mitocondrial. La investigación subraya las limitaciones de las mediciones periféricas actuales de oxígeno e introduce un cambio de paradigma hacia el monitoreo de la oxigenación específico por tejido.
La tecnología MDX Viewer de la compañía, combinada con su Universal Oxygen Carrier (UOC) y los programas de desarrollo BXT-25, pretende revolucionar los enfoques terapéuticos para condiciones como el ictus y la enfermedad de Alzheimer. La tecnología servirá como un biomarcador clave en los próximos ensayos clínicos BXT-25, con el potencial de transformar la forma en que se mide y gestiona la entrega de oxígeno en situaciones críticas.
Bioxytran (OTCQB: BIXT)는 조직 산소화와 미토콘드리아 기능에 관한 Avraham Mayevsky 교수의 획기적인 저서 발간으로 중요한 과학적 진전을 발표했습니다. 해당 연구는 현재 말초 산소 측정의 한계를 강조하고 조직 특이적 산소화 모니터링으로의 패러다임 전환을 제시합니다.
회사의 MDX Viewer 기술은 Universal Oxygen Carrier(UOC)와 BXT-25 개발 프로그램과 함께 뇌졸중 및 알츠하이머병과 같은 질환에 대한 치료 접근법을 혁신하는 것을 목표로 합니다. 이 기술은 향후 BXT-25 임상시험에서 중요한 바이오마커로 사용되어 중증 상황에서 산소 전달을 측정하고 관리하는 방식을 바꿀 가능성이 있습니다.
Bioxytran (OTCQB: BIXT) a annoncé une avancée scientifique majeure avec la publication d’un ouvrage révolutionnaire du Prof. Avraham Mayevsky sur l’oxygénation tissulaire et la fonction mitochondriale. La recherche souligne les limites des mesures périphériques d’oxygène actuelles et introduit un changement de paradigme vers la surveillance de l’oxygénation spécifique aux tissus.
La technologie MDX Viewer de la société, combinée à leur Universal Oxygen Carrier (UOC) et aux programmes de développement BXT-25, vise à révolutionner les approches thérapeutiques pour des affections telles que l’accident vasculaire cérébral et la maladie d’Alzheimer. La technologie servira de biomarqueur crucial dans les prochains essais cliniques BXT-25, pouvant transformer la façon dont l’apport en oxygène est mesuré et géré dans les situations critiques.
Bioxytran (OTCQB: BIXT) gab einen bedeutenden wissenschaftlichen Fortschritt bekannt: die Veröffentlichung eines wegweisenden Buches von Prof. Avraham Mayevsky über Gewebeoxygenierung und Mitochondrienfunktion. Die Forschung hebt die Grenzen aktueller peripherer Sauerstoffmessungen hervor und schlägt einen Paradigmenwechsel hin zu gewebespezifischem Oxygenierungs-Monitoring vor.
Die MDX Viewer-Technologie des Unternehmens, kombiniert mit dem Universal Oxygen Carrier (UOC) und den Entwicklungsprogrammen BXT-25, zielt darauf ab, Behandlungsansätze bei Erkrankungen wie Schlaganfall und Alzheimer zu revolutionieren. Die Technologie wird als wichtiger Biomarker in kommenden BXT-25-Studien dienen und könnte die Messung und Steuerung der Sauerstoffzufuhr in kritischen Zuständen grundlegend verändern.
Positive
- Development of advanced tissue-specific oxygenation monitoring technology
- Integration of MDX Viewer technology as a biomarker for BXT-25 clinical trials
- Potential applications in major markets including stroke and Alzheimer’s treatment
Negative
- Clinical trials for BXT-25 still pending
- Technology remains in development phase with no immediate revenue generation
08/15/2025 – 12:13 PM
- Game changer for stroke, Alzheimer’s, and beyond
- Shifting from peripheral to tissue-specific oxygenation monitoring
BOSTON – Bioxytran (OTCQB: BIXT) is making a bold move into next-generation oxygen therapeutics, announcing the publication of a key scientific work. Prof. Avraham Mayevsky’s “Body Oxygen Homeostasis and Mitochondrial Function from Animal Models to Clinical Applications” is set to disrupt current medical practices, which often rely on outdated peripheral oxygen measurements. The research highlights the critical need for tissue-specific oxygen monitoring to understand what’s really happening inside vital organs, paving the way for precision diagnostics and treatments.
https://link.springer.com/book/10.1007/978-3-031-94113-9
Imagine a stroke patient with seemingly perfect oxygen saturation levels, yet their brain is starved of oxygen. This is the gap Mayevsky’s research addresses, bridging animal studies with real-world clinical applications. Bioxytran aims to leverage these insights with its Universal Oxygen Carrier (UOC) and upcoming BXT-25 clinical trials. Integrating FDA-approved tools, like the MDX Viewer, into clinical settings is expected to lead to better outcomes in the operating room and beyond.
Bioxytran’s BXT-25 clinical trials will use the MDX Viewer as a crucial biomarker, capable of advancing the trials thanks to its ability to measure oxygen consumption in the brain during a stroke.
“Bioxytran is poised to lead the oxygen therapeutics revolution,” notes Avraham Mayevsky, Member of Bioxytran’s Medical Advisory Board. “The principles in this book, tracing tissue oxygenation, could accelerate treatments for stroke, chronic wounds, and even Alzheimer’s—where restoring oxygen delivery may slow neurodegeneration.”
About Bioxytran, Inc.
Bioxytran, Inc. is focused on developing carbohydrate-based therapeutics to address major unmet medical needs across three platform technologies: virology, cancer metastasis, and oxygen transport. Alongside ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. The company believes BXT-25 could significantly reduce the time to treatment for stroke patients. For more information, visit www.bioxytraninc.com
Forward-Looking Statements
This press release contains forward-looking statements subject to federal law. These statements involve risks, assumptions, and uncertainties. Factors that could cause actual results to differ materially are detailed in Bioxytran’s filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to update these statements except as required by law.
FAQ
What is Bioxytran’s (BIXT) new breakthrough in tissue oxygenation monitoring?
Bioxytran has developed technology for tissue-specific oxygenation monitoring, moving beyond traditional peripheral measurements to provide more accurate readings of oxygen levels in vital organs.
How will BIXT’s technology impact stroke treatment?
The technology will serve as a biomarker in BXT-25 clinical trials, measuring brain oxygen consumption during stroke, potentially leading to more effective treatments through targeted oxygen delivery.
What markets is Bioxytran (BIXT) targeting with its oxygen monitoring technology?
Bioxytran is targeting markets including stroke treatment, Alzheimer’s disease, and chronic wounds where precise oxygen delivery monitoring could improve patient outcomes.
Who is Prof. Avraham Mayevsky and what is his role at Bioxytran (BIXT)?
Prof. Mayevsky is a key advisor to Bioxytran and member of their Medical Advisory Board who published groundbreaking research on body oxygen homeostasis and mitochondrial function.
What is the significance of Bioxytran’s MDX Viewer technology?
The MDX Viewer is an FDA-approved tool that enables tissue-specific oxygenation monitoring, offering more precise measurements than traditional peripheral oxygen monitoring methods.
